Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 68

Results For "stent"

930 News Found

Healthcare Global Enterprises revenue up 19%
News | February 10, 2023

Healthcare Global Enterprises revenue up 19%

Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations


Windlas Biotech appoints Komal Gupta as CEO
People | February 09, 2023

Windlas Biotech appoints Komal Gupta as CEO

The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO


Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
News | February 09, 2023

Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%

Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore


Lupin receives tentative approval from USFDA for DETAF tablets
Drug Approval | February 01, 2023

Lupin receives tentative approval from USFDA for DETAF tablets

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries


Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai
Healthcare | January 25, 2023

Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai

Medical Tourism will boost India’s economy


US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
News | January 23, 2023

US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial


Pfizer expands ‘An Accord for a Healthier World’ product offering in 45 lower-income countries
Healthcare | January 23, 2023

Pfizer expands ‘An Accord for a Healthier World’ product offering in 45 lower-income countries

Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences
News | January 10, 2023

Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences

In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”